Nutrileads B.V. announced the successful closing of a Series A financing round with existing shareholders DSM Venturing, PPM Oost, Shift Invest and Thuija Capital. NutriLeads develops supportive nutritional ingredients for application in dietary supplements, medical food and functional food products intended for specific target populations seeking to support their immune function. Its lead ingredient aims to support immune function and increase resistance to common infectious diseases such as colds and flu.
A proof of concept study in human volunteers showed an excellent tolerability and safety profile. More importantly, a dose-dependent effect regarding the enhancement of immune function was demonstrated. In addition to these positive clinical results, a recent production pilot showed the feasibility of a cost-effective and sustainable production process for its lead ingredient.
The current Series A financing will be used to support the further development of NutriLead’s lead ingredient, a novel Immune Modulating Plant Polysaccharide. During the next phase, production will be scaled up and two human clinical trials to substantiate the immune supportive effect in different target populations will be performed.
Ruud Albers, PhD, CEO of NutriLeads
“The current investment supports the fast track development of our lead ingredient for application in dietary supplements, medical foods and functional foods. We are confident that this will help us realize our ambition to partner with ingredient suppliers and food companies to bring the benefits of our health ingredients to patients and consumers”,
NutriLeads B.V. is an innovative Nutrition & Health startup that develops food ingredients with demonstrated health effects for specific consumer groups. Founded in 2012 the company identifies promising lead ingredients, develops sustainable and commercially viable production processes and initiates scientific and clinical programs to test the health effects. Nutrileads participated in the Venture Challenge Fall 2013.